{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:48:33Z","timestamp":1779230913801,"version":"3.51.4"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health's National Center for Advancing Translational Sciences","award":["UM1TR004405"],"award-info":[{"award-number":["UM1TR004405"]}]},{"name":"National Institutes of Health's National Center for Advancing Translational Sciences","award":["UM1TR004405"],"award-info":[{"award-number":["UM1TR004405"]}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["00451A121"],"award-info":[{"award-number":["00451A121"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NICE-CF, PROMISE-OB-18, DIGEST 4, and STRONG-CF"],"award-info":[{"award-number":["NICE-CF, PROMISE-OB-18, DIGEST 4, and STRONG-CF"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Gastrointestinal (GI) complications are the second most common disorders in persons with cystic fibrosis (PwCF). There is limited data on how having a dedicated CF-GI clinic and cystic fibrosis transmembrane conductance regulator (CFTR) modulators may affect rates of GI complications. Our aim was to assess the effect of the CF-GI clinic and CFTR modulators on GI complications with incidence of distal intestinal obstructive syndrome (DIOS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective study of adult PwCF who were seen in a CF-GI clinic from 2000\u20132023. Comparisons were made between the numbers of admissions and emergency department (ED) visits for DIOS at three years before and after CFTR modulator use and the first CF-GI clinic visit.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of the 1,076 PwCF identified, 242 were seen in CF-GI clinic. Of this, 126 (52.1%) were female, with a median age of 40 (IQR: 30\u201347) years. There were 146 (60.3%) with regular use of laxatives. Of the 59 PwCF with CF-GI clinic visits for constipation, hospital admissions decreased in 16, were unchanged in 32, and increased in 11 (<jats:italic>p<\/jats:italic>\u2009=\u20090.402) while ED visits decreased in 9, remained the same in 40, and increased in 10 (<jats:italic>p<\/jats:italic>\u2009=\u20090.862). Of the 125 PwCF with CFTR modulator use, DIOS-related hospital admissions decreased in 15 patients, remained unchanged in 89, and increased in 21 (<jats:italic>p<\/jats:italic>\u2009=\u20090.021) while ED visits were fewer in 8, unchanged in 97, and increased in 20 (<jats:italic>p<\/jats:italic>\u2009=\u20090.587).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>PwCF had high burden of constipation with a majority of patients regularly using laxatives, and almost half had a history of DIOS. CFTR modulator use and CF-GI clinic were not associated with a decrease of DIOS incidence.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0328015","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T17:32:41Z","timestamp":1753723961000},"page":"e0328015","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-413X","authenticated-orcid":true,"given":"Nicha","family":"Wongjarupong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malique F.","family":"Delbrune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameel","family":"Alp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne M.","family":"Moutsoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Wiggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-5772","authenticated-orcid":true,"given":"Ashley","family":"Benner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne L.","family":"Billings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan M.","family":"Dunitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Schwarzenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baharak","family":"Moshiree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"2","key":"pone.0328015.ref001","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"B Moshiree","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"pone.0328015.ref002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1542\/peds.78.3.473","article-title":"Constipation and meconium ileus equivalent in patients with cystic fibrosis","volume":"78","author":"S Rubinstein","year":"1986","journal-title":"Pediatrics"},{"issue":"6","key":"pone.0328015.ref003","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jped.2020.03.004","article-title":"Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies","volume":"96","author":"MA Stefano","year":"2020","journal-title":"J Pediatr (Rio J)"},{"issue":"6","key":"pone.0328015.ref004","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1542-3565(04)00169-7","article-title":"Distal intestinal obstruction syndrome in adults with cystic fibrosis","volume":"2","author":"X Dray","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0328015.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2017.06.013","article-title":"Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer","volume":"16","author":"JM Abraham","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"1","key":"pone.0328015.ref006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPG.0b013e3181a6e01d","article-title":"Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS","volume":"50","author":"RH Houwen","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"pone.0328015.ref007","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","volume":"22","author":"SJ Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"pone.0328015.ref008","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation.","volume":"2017","author":"PM Farrell","journal-title":"J Pediatrics"},{"issue":"1","key":"pone.0328015.ref009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jcf.2009.11.003","article-title":"Constipation in pediatric cystic fibrosis patients: an underestimated medical condition","volume":"9","author":"HPJ van der Doef","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"3","key":"pone.0328015.ref010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2009.05.037","article-title":"Activation of Intestinal Cl- Secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator","volume":"137","author":"MJC Bijvelds","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0328015.ref011","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00261.2017","article-title":"Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium\/hydrogen exchanger 3","volume":"315","author":"DR McHugh","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"pone.0328015.ref012","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/bph.15323","article-title":"Inhibition of Na(+)\/H(+) exchanger isoform 3 improves gut fluidity and alkalinity in cystic fibrosis transmembrane conductance regulator-deficient and F508del mutant mice","volume":"178","author":"Q Tan","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"3","key":"pone.0328015.ref013","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00388.2021","article-title":"Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway","volume":"322","author":"CA Shaughnessy","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"9","key":"pone.0328015.ref014","first-page":"1061","article-title":"Lubiprostone for constipation in adults with cystic fibrosis: a pilot study","volume":"201145","author":"CE O\u2019Brien","journal-title":"Ann Pharmacother"},{"issue":"6","key":"pone.0328015.ref015","article-title":"Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.","volume":"12","author":"W Carroll","year":"2021","journal-title":"Cochrane Datab Syst Rev"},{"issue":"5","key":"pone.0328015.ref016","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-3476(05)83350-5","article-title":"Effects of cisapride in patients with cystic fibrosis and distal intestinal obstruction syndrome","volume":"117","author":"S Koletzko","year":"1990","journal-title":"J Pediatrics"},{"issue":"1","key":"pone.0328015.ref017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.123.1.37","article-title":"GI complications after lung transplantation in patients with cystic fibrosis","volume":"123","author":"M Gilljam","year":"2003","journal-title":"Chest"},{"issue":"155","key":"pone.0328015.ref018","doi-asserted-by":"crossref","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"M Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"1","key":"pone.0328015.ref019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"RVE Dagenais","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0328015.ref020","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.1038\/s41598-023-35942-7","article-title":"Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns","volume":"13","author":"S Desai","year":"2023","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T17:32:44Z","timestamp":1753723964000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328015"}},"subtitle":[],"editor":[{"given":"Alyssa","family":"Kriegermeier","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328015","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}